title: [Thyroid hormones and cardiovascular system].
abstract: Cardiovascular system is essentially affected by thyroid hormones by way of their genomic and non-genomic effects. Untreated overt thyroid dysfunction is associated with higher cardiovascular risk. Although it has been studied more than 3 decades, in subclinical thyroid dysfunction the negative effect on cardiovascular system is much more controversial. Large meta-analyses within last 10 years have shown that subclinical hyperthyroidism is associated with higher cardiovascular risk than subclinical hypothyroidism. Conversely, in patients of age > 85 years subclinical hypothyroidism was linked with lower mortality. Therefore, subclinical hyperthyroidism should be rather treated in the elderly while subclinical hypothyroidism in the younger patients and the older may be just followed. An important problem on the border of endocrinology and cardiology is amiodarone thyroid dysfunction. Effective and safe treatment is preconditioned by distinguishing of type 1 and type 2 amiodarone induced hyperthyroidism. The type 1 should be treated with methimazol, therapeutic response is prolonged, according to recent knowledge immediate discontinuation of amiodarone is not routinely recommended and patient should be usually prepared to total thyroidectomy, or rather rarely 131I radioiodine ablation may be used if there is appropriate accumulation. In the type 2 there is a promt therapeutic response on glucocorticoids (within 1-2 weeks) with permanent remission or development of hypothyroidism. If it is not used for life-threatening arrhytmias, amiodarone may be discontinuated earlier (after several weeks). Amiodarone induced hypothyroidism is treated with levothyroxine without amiodarone interruption.Key words: amiodarone induced thyroid dysfunction - atrial fibrillation - cardiovascular risk - heart failure - hyperthyroidism - hypothyroidism - thyroid stimulating hormone.
authors.forename: Zdeňka
authors.initials: Z
authors.lastname: Límanová
authors.forename: Jan
authors.initials: J
authors.lastname: Jiskra
mesh_terms: D000328:Adult; D000369:Aged, 80 and over; D000638:Amiodarone / Q000009:adverse effects*; D013956:Antithyroid Agents / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy*; D002309:Cardiology; D002319:Cardiovascular System; D005938:Glucocorticoids / Q000627:therapeutic use; D006333:Heart Failure; D006801:Humans; D006980:Hyperthyroidism / Q000139:chemically induced* / Q000628:therapy; D007037:Hypothyroidism / Q000139:chemically induced* / Q000188:drug therapy; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008713:Methimazole / Q000627:therapeutic use; D012307:Risk Factors; D013963:Thyroid Hormones; D013974:Thyroxine / Q000627:therapeutic use
chemical_list: D013956:Antithyroid Agents; D005938:Glucocorticoids; D007457:Iodine Radioisotopes; D013963:Thyroid Hormones; D008713:Methimazole; D000638:Amiodarone; D013974:Thyroxine